HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Skehan, S. J. Articles by Peters, A. M. Search for Related Content PubMed PubMed Citation Articles by Skehan, S. J. Articles by Peters, A. M.

Mechanism of Accumulation of ^99mTc-Sulesomab in Inflammation

¹ Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, United Kingdom
² Department of Medicine, Addenbrooke’s and Papworth Hospitals, Cambridge, United Kingdom

View larger version (25K): [in a new window]   FIGURE 1. Binding of 99mTc-sulesomab and 99mTc-HSA (A) and 18F-FDG (B) to quiescent control, TNF--primed, and TNF--primed, fMLP fully activated granulocytes, shown as percentage uptake of available tracer by cells (mean ± SE). 99mTc-Sulesomab or 99mTc-HSA was added to suspension of granulocytes after they had been incubated with TNF- (or PBS) for 30 min and exposed to fMLP (or PBS) for additional 5 min. 18F-FDG was added to suspension of granulocytes after they had been incubated with TNF- (or PBS) for 30 min and immediately before addition of fMLP (or PBS). Data are corrected for nonspecific binding (n = 3 for each column). *Significant difference compared with control cells at P < 0.05. Significant difference compared with control cells at P < 0.005.

View larger version (19K): [in a new window]   FIGURE 2. Blood clearances of 99mTc-sulesomab (A) and 99mTc-HSA (B) in each individual subject. Symbol shapes (filled and open symbols) here and in Figure 4 correspond to 1 individual patient.

View larger version (30K): [in a new window]   FIGURE 3. Radioprotein images of patient with septic arthritis of elbow acquired 1, 3, 4, and 6 h after injection: (A) 99mTc-HSA; (B) 99mTc-sulesomab. 99mTc-Methylene diphosphonate images (C) and 22-h 111In-leukocyte images (D) are shown for comparison.

View larger version (22K): [in a new window]   FIGURE 4. P-R plots illustrate tissue clearance of 99mTc-sulesomab (filled symbols, bold lines) and 99mTc-HSA (open symbols, fine lines) in all 7 patients. Symbol shapes correspond to same patients as in Figure 2. (A) Site of infection. (B) Control tissue.

View larger version (13K): [in a new window]   FIGURE 5. Correlation between T/Bkg ratios of 99mTc-sulesomab and 99mTc-HSA (6 h) (A) and between T/Bkg ratios of 111In-leukocytes (22 h) and 99mTc-sulesomab and 99mTc-HSA (6 h) (B).